Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gregory Maniatis

Interventional Cardiology Staten Island, NY Medical Doctor

NPI 1932499290 CMS profile 1387449

501 Seaview Ave Ste 200, Staten Island, NY 10305

Open in the dashboard

General payments

$7,932

112 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gregory Maniatis of Staten Island, NY is reported in the CMS Open Payments database as having received $7,932 across 112 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 52nd percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,641 16
2024 General $1,670 21
2023 General $2,075 37
2022 General $1,062 14
2021 General $706 13
2020 General $413 4
2019 General $364 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gregory Maniatis
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Gregory Maniatis were reported at $1,641. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Gregory Maniatis Interventional Cardiology median Middle half National median
2019 $364 $1,097 $329–$3,048 $163
2020 $413 $473 $161–$1,480 $114
2021 $706 $677 $233–$1,827 $132
2022 $1,062 $978 $333–$2,724 $149
2023 $2,075 $1,136 $382–$2,986 $160
2024 $1,670 $1,181 $395–$3,326 $164
2025 $1,641 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $2,194 34 payments
  2. Abbott Laboratories $1,748 28 payments
  3. Edwards Lifesciences Corporation $1,217 18 payments
  4. Philips Electronics North America Corporation $838 11 payments
  5. Boston Scientific Corporation $700 5 payments
  6. Medtronic Vascular, Inc. $449 5 payments
  7. SpectraWAVE, Inc $320 2 payments
  8. Teleflex LLC $143 1 payment
  9. Terumo Medical Corporation $131 1 payment
  10. Abiomed $88 3 payments
  11. Other $105 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,932 112 payments
Products named General payments · program years 2019–2025
  1. COREVALVE EVOLUT R $1,547 24 payments
  2. SAPIEN 3 Ultra RESILIA $529 6 payments
  3. MITRACLIP $517 6 payments
  4. CoreValve Evolut Transcatheter Valve Systems $322 4 payments
  5. Starlight Imaging Catheter $320 2 payments
  6. HyperVue Imaging System $320 2 payments
  7. (6575) Coronary Undivided $310 3 payments
  8. DRAGONFLY OPSTAR $285 2 payments
  9. SYNERGY $276 2 payments
  10. CoreValve Evolut Transcatheter Valve Systems $263 3 payments
  11. Other $3,271 58 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

685

Median for Cardiology: 2,533

Drug cost

$127,771

Median for Cardiology: $485,213

Branded share of claims

21.3%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 89 $90,723
Entresto Sacubitril/Valsartan Brand 23 $30,647
Metoprolol Succinate Generic 124 $1,739
Atorvastatin Calcium Generic 119 $1,224
Valsartan-Hydrochlorothiazide Valsartan/Hydrochlorothiazide Brand 17 $782
Amlodipine Besylate Generic 55 $426
Losartan Potassium Generic 34 $343
Torsemide Generic 15 $263
Rosuvastatin Calcium Generic 26 $260
Furosemide Generic 48 $203

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$218,350

Medicare's payments for the services billed

Medicare patients

569

Average age 76

Services billed

2,024

277 women, 292 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 63%
Diabetes 56%
Arthritis 54%
Heart failure 46%
Atrial fibrillation 41%
Chronic kidney disease 33%
COPD 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

112 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record